In May, Scantox has submitted its greenhouse gas reduction targets to SBTi Services for validation. This is an important milestone in our sustainability journey, and a step that marks our transition from internally set and lender‑linked ESG targets to a broader, science‑based climate framework.
Our submission covers Scope 1, Scope 2, and Scope 3 emissions, reinforcing our ambition to align long‑term business growth with credible, value‑chain decarbonisation.
The Science Based Targets initiative (SBTi) supports organizations in setting emissions reduction targets grounded in climate science. By providing guidance, technical support, and independent validation, SBTi enables more than 2,000 companies globally to contribute meaningfully to a net‑zero future.
We look forward to continuing this work as part of our commitment to responsible growth and climate action.
About Scantox:
Scantox is an integrated preclinical CRO supporting sponsors from discovery through IND-enabling nonclinical development, with operations in Denmark, Sweden, Austria, and the United Kingdom. We combine Discovery, Regulatory Toxicology, Pharmaceutical Development & Analytical, and Genetic Toxicology in one coordinated platform, helping clients generate high-quality, regulator-ready data while keeping timelines and execution aligned across disciplines. Scantox is recognized for deep expertise in CNS pharmacology and Göttingen minipig research, with advanced genetic toxicology and genomic safety capabilities including Big Blue® transgenic rodent assays and DuplexSeq™ mutagenesis testing. Founded in 1977, Scantox is owned by Impilo, the leading Nordic healthcare investment company.
Press contact:
Tina Andersen, Marketing Manager Scantox Group, tia@scantox.com
